Vision

Isofol’s medicine aims to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life.

Mission

Our mission is to make arfolitixorin available worldwide, improving outcomes for cancer patients undergoing chemotherapy. As an initial focus, Isofol is working to secure regulatory approval for arfolitixorin in the treatment of metastatic colorectal cancer – the second leading cause of cancer-related deaths globally. With a five-year survival rate of only 14%, there is a critical need to advance treatment options for these patients.

Next-generation folate therapy

Arfolitixorin represents a new class of folate that, unlike currently available treatments, does not require metabolic conversion in the body to become active. This mechanism is expected to deliver significant efficacy advantages.

Building on the clinical evidence and scientific knowledge generated for arfolitixorin to date, strong partnerships established with leading clinical experts and other collaborators, and deep in-house expertise, Isofol is well-positioned to advance the clinical development of arfolitixorin.

Our goal is clear:

To improve cancer treatment for millions of patients while creating substantial value for shareholders, employees, and society. We are entering an exciting new phase in the company’s development.